Clinical Trials
48 trialsA Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
Jiangsu Province Nanjing Brain Hospital
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis
Jiangsu Province Nanjing Brain Hospital
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC
Taixing People's Hospital
HALT
Institute of Cancer Research, United Kingdom
A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer
Northern Jiangsu People's Hospital
MRDinS3LC
Peking University Cancer Hospital & Institute
The Efficacy and Safety of KN046 Combined With Axitinib
Shanghai Pulmonary Hospital, Shanghai, China
CAPLAND
Fondazione Ricerca Traslazionale
18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Milciclib in Combination With Gemcitabine in Advanced NSCLC
Tiziana Life Sciences LTD
PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial
The First Affiliated Hospital of Zhengzhou University
NSCLC
Henan Cancer Hospital
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor
Genor Biopharma Co., Ltd.
Study of HA121-28 in Patients With Non-Small Cell Lung Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
pcwaintrl
Tang-Du Hospital
Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
The First Affiliated Hospital of Henan University of Science and Technology
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation
Shanghai Henlius Biotech
ATHEM
Tongji University
CAMFA-L
Shanghai Chest Hospital
JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety
Beijing Dongfang Biotech Co., Ltd.
TUMOVASC
University Hospital, Strasbourg, France
Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
NSCLC
Fudan University
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
Jiangsu HengRui Medicine Co., Ltd.
BELLA
Guangdong Association of Clinical Trials
Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer
Henan Cancer Hospital
Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer
Peking Union Medical College Hospital
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Guangdong Association of Clinical Trials
AFLC
Shenzhen People's Hospital
ALTER-L013
Tongji Hospital
RCTACSCNSCLC
Shenzhen People's Hospital
Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients
K2 Oncology, Inc.
Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)
Affiliated Hospital of North Sichuan Medical College
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
Shanghai University of Traditional Chinese Medicine
INCREASE
Betta Pharmaceuticals Co., Ltd.
Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer
Shanghai Chest Hospital
Conmana Combined With Thalidomide to Treat NSCLC
Henan Provincial People's Hospital
S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC
Sun Yat-sen University
Circulating Fibrocytes in Non-small Cell Lung Cancer.
Chang Gung Memorial Hospital
Gefitinib Combined With Thalidomide to Treat NSCLC
Shaanxi Provincial People's Hospital
Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer
Nanfang Hospital, Southern Medical University
Afatinib Plus Nimotuzumb for NSCLC
Samsung Medical Center
A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status
National University Hospital, Singapore
An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib
Sheba Medical Center
FACPT
The First Affiliated Hospital of Guangzhou Medical University